SGHI FHIR Profile Implementation Guide, published by Kathurima Kimathi. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/savannahghi/sil_fhir_profile_ig/ and changes regularly. See the Directory of published versions

• Narrative Content
• XML
• JSON
• TTL

: SGHI Systemic Anti-Cancer Therapy - JSON Representation

Active as of 2026-10-02

Raw json | Download

{
  "resourceType" : "ValueSet",
  "id" : "anti-cancer-therapy",
  "text" : {
    "status" : "extensions",
    "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p class=\"res-header-id\"><b>Generated Narrative: ValueSet anti-cancer-therapy</b></p><a name=\"anti-cancer-therapy\"> </a><a name=\"hcanti-cancer-therapy\"> </a><ul><li>Include these codes as defined in <a href=\"CodeSystem-answer-codesystem.html\"><code>https://fhir.slade360.co.ke/fhir/CodeSystem/answer-codesystem</code></a><span title=\"Version is not explicitly stated, which means it is fixed to the version provided in this specification\"> version &#x1F4E6;0.1.0</span><table class=\"none\"><tr><td style=\"white-space:nowrap\"><b>Code</b></td><td><b>Display</b></td><td><b>Definition</b></td></tr><tr><td><a href=\"CodeSystem-answer-codesystem.html#answer-codesystem-anti-cancer-chemotherapy\">anti-cancer-chemotherapy</a></td><td>Chemotherapy</td><td>Cytotoxic chemotherapy. Recorded on the cancer centre informed consent.</td></tr><tr><td><a href=\"CodeSystem-answer-codesystem.html#answer-codesystem-anti-cancer-hormonal-therapy\">anti-cancer-hormonal-therapy</a></td><td>Hormonal therapy</td><td>Hormonal therapy, such as an LHRH agonist, an anti-androgen, an anti-oestrogen or an aromatase inhibitor. Recorded on the cancer centre informed consent.</td></tr><tr><td><a href=\"CodeSystem-answer-codesystem.html#answer-codesystem-anti-cancer-targeted-therapy\">anti-cancer-targeted-therapy</a></td><td>Targeted therapy</td><td>Targeted therapy against a molecular feature of the cancer, such as a HER2 antibody or a tyrosine kinase inhibitor. Recorded on the cancer centre informed consent.</td></tr></table></li></ul></div>"
  },
  "url" : "https://fhir.slade360.co.ke/fhir/ValueSet/anti-cancer-therapy",
  "version" : "0.1.0",
  "name" : "SGHIAntiCancerTherapy",
  "title" : "SGHI Systemic Anti-Cancer Therapy",
  "status" : "active",
  "experimental" : false,
  "date" : "2026-10-02T07:33:51+00:00",
  "publisher" : "Kathurima Kimathi",
  "contact" : [
    {
      "name" : "Kathurima Kimathi",
      "telecom" : [
        {
          "system" : "url",
          "value" : "https://www.linkedin.com/in/kathurima-kimathi/"
        },
        {
          "system" : "email",
          "value" : "kathurimakimathi415@gmail.com"
        }
      ]
    },
    {
      "name" : "Oscar John",
      "telecom" : [
        {
          "system" : "email",
          "value" : "oscarjohnotieno@gmail.com",
          "use" : "work"
        }
      ]
    },
    {
      "name" : "Kennedy Omondi",
      "telecom" : [
        {
          "system" : "email",
          "value" : "kennankole@gmail.com",
          "use" : "work"
        }
      ]
    }
  ],
  "description" : "The kinds of systemic anti-cancer therapy the cancer centre informed consent covers: chemotherapy, hormonal therapy and targeted therapy. The paper prints them as one line to strike through; this asks which apply, and more than one can.",
  "compose" : {
    "include" : [
      {
        "system" : "https://fhir.slade360.co.ke/fhir/CodeSystem/answer-codesystem",
        "concept" : [
          {
            "code" : "anti-cancer-chemotherapy",
            "display" : "Chemotherapy"
          },
          {
            "code" : "anti-cancer-hormonal-therapy",
            "display" : "Hormonal therapy"
          },
          {
            "code" : "anti-cancer-targeted-therapy",
            "display" : "Targeted therapy"
          }
        ]
      }
    ]
  }
}